Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 7/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718626 | 0.90 | RPS6KA3 (0.45) | RPS6KA3DGAT2CHRM5 | |
| SCHEMBL6719133 | 0.84 | KCNA5 (0.45) | RPS6KA3DGAT2KCNA5KCNH2 | |
| SCHEMBL6719208 | 0.83 | SLC22A12 (0.50) | RPS6KA3DGAT2KCNA5KCNH2 | |
| SCHEMBL6721866 | 0.83 | RPS6KA3 (0.56) | RPS6KA3 | |
| SCHEMBL6729001 | 0.82 | RPS6KA3 (0.39) | RPS6KA3DGAT2 | |
| SCHEMBL6718921 | 0.82 | RPS6KA3 (0.39) | RPS6KA3DGAT2 | |
| SCHEMBL6723256 | 0.82 | KCNA5 (0.46) | DHODHCHRM5KCNA5KCNH2NPY5R | |
| SCHEMBL6730679 | 0.82 | RPS6KA3 (0.48) | RPS6KA3 | |
| SCHEMBL7537753 | 0.82 | RPS6KA3 (0.51) | RPS6KA3DHODHDGAT2NPY5RDYRK1A | |
| SCHEMBL6730188 | 0.81 | RPS6KA3 (0.44) | RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | RPS6KA3 972/4885DHODH 1994/4885DGAT2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.